ClinicalTrials.gg
Status unknownNCT02249663Updated Sep 25, 2014

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

A Phase 3 interventional study of Azelastine hydrochloride and Fluticasone propionate and Dymista™ in Seasonal Allergic Rhinitis, sponsored by Teva Pharmaceuticals USA. Status unknown at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2014-09-25.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3 and Interventional

The sponsor has not verified this record recently (last verified Sep 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,535
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing azelastine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. azelastine · Rhinitis, Allergic, Seasonal.

Planned enrollment
2nd of 16
1,535 · median 415
Started
2014
the only one that year
Phase 3
9 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Teva Pharmaceuticals USA

Among the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal, this one is the 2nd largest by planned enrollment, is the only one that started in 2014, is one of 9 in phase 3, and was the 11th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About azelastine

azelastine: first FDA approval 1996 (ASTELIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing azelastine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

To evaluate the therapeutic equivalence of a test formulation of Azelastine hydrochloride and Fluticasone propionate Nasal Spray to the reference listed drug, Dymista™ Nasal Spray in the relief of the signs and symptoms of Seasonal Allergic Rhinitis.

03

Conditions studied

  • Seasonal Allergic Rhinitis

Keywords

  • Bioequivalence
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating female 12 years of age or older.
  • Signed form, which meets all criteria of current FDA regulations. For patients under the age of majority in the state the study is being conducted (18 years in most states) the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form that will be written in such a way to be understandable to a child.
  • Documented positive allergic skin test, performed within the previous 12 months, to one or more of the allergens in season at the time the study is being conducted.
  • A minimum of two consecutive years of previous history of Seasonal Allergic Rhinitis (SAR) to the pollen/allergen in season at the time the study is being conducted.
  • Eligibility requirements for placebo lead-in period: A total (composite) score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) with a minimum of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms and total (composite) score of at least 4 on the reflective Total Ocular Symptom Score (rTOSS). These scores represent the 12 hours before the screening visit.
  • In addition to requirements above, patients should have the following at the end of the placebo lead-in period and before randomization: 1) average composite score of at least 6 on the rTNSS with a minimum average score of at least 2 for "nasal congestion" and a minimum average score of at least 2 for one of the remaining 3 symptoms, and 2) average composite score of at least 4 on the rTOSS. These scores represent the 3 days of the 7 day placebo run-in period before the Randomization visit and the morning of the first day of the Randomization visit.

Exclusion criteria

Exclusion Criteria:

  • Under 12 years of age.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Negative or lack of documented skin allergen test (performed within the previous 12 months) to at least one of the allergens in season at the time the study is being conducted. The results of all positive skin allergen test results should be reported.
  • Patients who suffer from chronic signs and symptoms of Perennial Allergic Rhinitis (PAR) should be excluded from the study unless the Investigator assesses that the patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic Rhinitis (SAR) rather than the chronic PAR.
  • Patients who suffer only from PAR or SAR to a different allergen than that in season at the time the study is conducted.
  • Previous history of less than 2 years of SAR to the pollen/allergen in season at the time the study is conducted.
  • Before the placebo lead-in period, the patient has a total score of less than 6 on the rTNSS or a score less than 2 for "nasal congestion". Any patient who meets the minimum individual nasal symptom score requirements at the start of the placebo lead-in period but no longer meets the requirements prior to the randomized active treatment period of the study cannot continue in the active treatment period.
  • At the end of the placebo lead-in period and before randomization, the patient has an average composite score of less than 6 on the rTNSS and an average composite score of less than 4 on the rTOSS.
  • History of asthma over the previous 2 years that required chronic therapy. Occasional acute or mild exercise induced asthma will be allowable on the condition that the treatment of the attacks is restricted to beta-agonists only.
  • Patients with nasal conditions, including infectious rhinitis, rhinitis medicamentosa, or atrophic rhinitis.
  • nasal deformity or any recent nasal surgery or trauma that has not completely healed.
  • Sinus infection within the previous 30 days or history or re-occurring sinus infections.
  • Patient has started immunotherapy or changed their dose of immunotherapy within 30 days of the first placebo lead-in dose or is likely to have to start immunotherapy, or change their current dose during the study.
  • Treatment for oral Candidiasis within 30 days of starting the study or a current oral Candidiasis infection.
  • Upper respiratory tract infection within the previous 30 days.
  • Patients with a history of tuberculosis.
  • Patients with presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis, or other eye infection not related to the diagnosis of SAR within 14 days of enrollment.
  • The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
  • Patients with any untreated fungal, bacterial, or systemic viral infections within the previous 30 days.
  • Use of any ophthalmic within 14 days or nasal, inhaled, or systemic steroids within 30 days of the study start. Super or high potency topical steroids should not be used during the study.
  • Use of medications that significantly inhibit the cytochrome P450 subfamily enzyme .
  • Use of intranasal or systemic second-generation anti-histamines within 10 days or enrollment.
  • Use of intranasal cromolyn within 14 days of enrollment.
  • Use of intranasal or systemic first-generation anti-histamines, leukotriene receptor antagonsits or other nasal decongestants within 3 days of enrollment.
  • Use of any tricyclic anti-depressant within 30 days of enrollment.
  • Patients with attention-deficit disorder being treated with methylphenidate containing products that have not been on a stable regimen for at least the 30 previous days and who cannot remain of the same dose throughout the study.
  • Desensitization therapy to the seasonal allergen that is causing the patient's allergic rhinitis within the previous 6 months.
  • Previous SAR and/or PAR that has proven unresponsive to steroid therapy.
  • Any known to azelastine hydrochloride, fluticasone propionate, other steroids, or any components of the study nasal spray.
  • Significant history or current evidence of chronic infectious disease, system disorder, organ disorder, or other medical condition that in the Investigator's opinion would place the patient at undue risk by participating or could jeopardize the integrity of the study evaluations.
  • Receipt of any drug as part of a research study within 30 days prior to the first placebo lead-in dose.
  • Planned travel outside of the local area for more than 2 consecutive days or 3 days in total, during the patient's participation in the study.
  • Previous participation in this study.
  • The patient has a history of non-compliance with medication regimens or treatment protocols in previous clinical studies.
  • The patient is a member of the study staff or a member of the family of the investigational study staff.
  • The patient currently smokes cigarettes, cigars, and/or pipes and is a heavy smoker (for example, on average more than 10 cigarettes per day).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,535 participants (estimated)

Study arms

  • Experimental
    Investigational Test Product

    Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg

    Drug: Azelastine hydrochloride and Fluticasone propionate

  • Active comparator
    Reference Listed Drug

    Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg

    Drug: Dymista™

  • Placebo comparator
    Placebo

    Placebo Nasal Spray

    Other: Placebo

Interventions

  • DrugAzelastine hydrochloride and Fluticasone propionate

    Drug pages: Azelastine · Fluticasone

    137/50 mcg Nasal Spray

  • 137/50 mcg Nasal Spray

    Also known as: Azelastine hydrochloride and Fluticasone propionate (generic name)

  • OtherPlacebo

    Nasal spray with no pharmaceutically active content

06

What researchers measure

Primary outcomes

  1. Change from baseline in average AM/PM reflective Total Nasal Symptom Score (rTNSS).

    Time frame: Days 1 to 14

Secondary outcomes

  1. Change from baseline in average instantaneous Total Nasal Symptom Score (iTNSS).

    Time frame: Days 1 to 14

  2. Change from baseline in average reflective Total Ocular Symptom Score (iTOSS).

    Time frame: Days 1 to 14

  3. Change from baseline in average instantaneous Total Ocular Symptom Score (iTOSS).

    Time frame: Days 1 to 14

  4. Onset of Action

    Time frame: 4 hours post dose

07

Study locations

1 of 1 sites recruiting
  • Novum Pharmaceutical Research Services
    Pittsburgh, Pennsylvania 15206, United States
    Recruiting
    • Gail Gongas · Contact412-363-3300
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014 and a primary completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 25, 2014
Start
Aug 2014
Primary completionEst.
Feb 2015
Last update
Sep 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02249663
Responsible party
Sponsor
First posted
Sep 25, 2014
Start date
Aug 2014
Primary completion
Feb 2015 (estimated)
Last update
Sep 25, 2014

Study contacts

Darin Brimhall, DO, FACP
Contact
dbrimhall@novumprs.som
(702) 435-3739 ext. 370
Darin Brimhall, DO, FACP
principal investigator · Novum Pharmaceutical Research Services
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azelastine · Fluticasone

Start the discussion